Everlab, a Melbourne-based health platform powered by artificial intelligence, has secured a US$10 million seed round led by Left Lane Capital, a global growth equity firm. This funding aims to enhance Everlab’s international expansion, advance its AI healthtech platform, and introduce a comprehensive product ecosystem for lifelong preventive care.
Chronic diseases account for over 70% of global deaths, yet healthcare systems largely remain reactive. Everlab seeks to change this by offering a tiered membership model that integrates advanced diagnostics and digital consultations, providing personalized preventive care on a large scale. Members benefit from extensive screening services, including advanced blood tests, MRIs, DEXA scans, and more, with continuous support and personalized prevention plans. The Protocol membership provides year-round diagnostics and interventions at a reduced cost compared to traditional care models.
Central to Everlab’s innovation is its proprietary clinical platform, which uses AI to process complex health data, automate summaries, and recommend personalized actions. This integration within existing healthcare systems allows for real-time health records and earlier interventions. With significant demand and a waiting list of tens of thousands, Everlab is poised for substantial growth, aiming to become a leader in high-quality, prevention-focused care.
To date, Everlab has processed over a million biomarkers, revealing that 25% of tests show abnormal results, with 2.5% uncovering critical health conditions. Their personalized interventions have shown tangible health improvements, with over one-third of modifiable biomarkers improving after six months.
The recent funding will support Everlab in expanding its clinic network, engineering, and clinical teams, and advancing its AI infrastructure, paving the way for a global system of preventive healthcare.
